Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.

Medtronic is following a strategy that has worked well for Johnson & Johnson.

History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.

Published October 1, 2026 · Category: Finance

Overview

Johnson & Johnson's (NYSE:JNJ) stock has absolutely crushed Medtronic's (NYSE:MDT) over the last decade. The iconic healthcare giant has generated a nearly 200% total return over the last 10 years (11.6% annualized), compared with roughly 35% for the healthcare technology company (3.1% annualized).

However, while Johnson & Johnson's stock was the clear winner over the past decade, I think Medtronic could be the better investment over the next 10 years. Here's why.

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.